Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep

# Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep ## Overview Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep is a nucleoside analog antiviral medication used for the treatment of chronic hepatitis B virus (HBV) infection. ## Primary Indications * Chronic Hepatitis B infection in adults and pediatric patients. ## Adult Dosing * The recommended dose is **300 mg orally once daily**. * The maximum daily dose is **300 mg**. ## Pediatric Dosing * **Aged 12 years and older and weighing at least 35 kg:** 300 mg orally once daily. * **Aged 12 years and older and weighing less than 35 kg:** Dosing should be based on local protocol or a case-by-case basis, as specific weight-based recommendations are not definitively established. * **Younger than 12 years:** Safety and efficacy have not been established. ## Dose Adjustments * **Renal Impairment:** Dose adjustment is required for moderate to severe renal impairment (CrCl < 50 mL/min). Consult prescribing information for specific dose adjustments based on CrCl. * **Hepatic Impairment:** No dose adjustment is generally recommended for mild to moderate hepatic impairment. Use with caution in severe hepatic impairment. ## Contraindications * Hypersensitivity to the active ingredient or any excipients. ## Adverse Effects * **Common:** Headache, nausea, fatigue, dizziness, somnolence, insomnia, abdominal pain. * **Serious:** Lactic acidosis, severe hepatomegaly with steatosis, renal impairment, exacerbations of hepatitis B upon discontinuation, potential for nucleoside analog resistance. ## Key Drug Interactions * **Nephrotoxic drugs:** Concomitant use with other drugs that are nephrotoxic may increase the risk of renal adverse events. * **Other nucleoside/nucleotide analogs:** Concurrent use is generally not recommended due to potential for additive toxicity. ## Monitoring * **Hepatitis B viral load (HBV DNA):** To assess antiviral efficacy. * **Liver function tests (ALT, AST, bilirubin):** To monitor for hepatotoxicity and disease flares. * **Renal function (serum creatinine, eGFR):** Especially in patients with pre-existing renal impairment or those taking other nephrotoxic agents. * **Lactate levels:** If symptoms of lactic acidosis arise. * **Hepatitis B e antigen (HBeAg) and anti-HBe status:** For potential HBeAg seroconversion. ## Clinical Pearls * Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep should be taken orally once daily, with or without food. * Discontinuation of treatment may lead to severe acute exacerbations of hepatitis B. Monitor patients closely after discontinuation. * Educate patients on the importance of adherence to minimize the risk of resistance. * Combination therapy is generally not recommended outside of specific clinical trial settings or salvage therapy for treatment-experienced patients. *** *This information is intended for clinical professionals and does not replace the need to consult the official prescribing information or a drug compendium for complete details, including a comprehensive list of adverse effects, contraindications, and drug interactions.*